148
Participants
Start Date
November 16, 2021
Primary Completion Date
September 9, 2022
Study Completion Date
September 19, 2023
Donanemab
Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
Aducanumab
Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Abington Neurological Associates, Ltd., Abington
The Clinical Trial Center, LLC, Jenkintown
National Clinical Research, Inc, Richmond
Columbus Memory Center, PC, Columbus
Charter Research - Lady Lake, Lady Lake
Jacksonville Center for Clinical Research, Jacksonville
ClinCloud - Maitland, Maitland
Conquest Research, Winter Park
ClinCloud - Viera, Melbourne
Merritt Island Medical Research, LLC, Merritt Island
Infinity Clinical Research, LLC, Hollywood
Optimus U Corporation, Miami
Brainstorm Research, Miami
Brain Matters Research, Delray Beach
JEM Research Institute, Atlantis
Axiom Clinical Research of Florida, Tampa
Neuropsychiatric Research Center of Southwest Florida, Fort Myers
Brain Matters Research, Stuart
Neurology Diagnostics, Inc., Dayton
Josephson Wallack Munshower Neurology, PC, Indianapolis
Clinical Research Professionals, Chesterfield
Kerwin Medical Center, Dallas
Las Vegas Medical Research, Las Vegas
California Neuroscience Research Medical Group, Inc., Sherman Oaks
Irvine Clinical Research, Irvine
Neurology Center of North Orange County, Fullerton
Institute for Neurodegenerative Disorders, New Haven
Donald S. Marks M.D., P.C., Plymouth
Adams Clinical, Watertown
The Cognitive and Research Center of New Jersey, Springfield
Advanced Memory Research Institute of New Jersey, Toms River
Eli Lilly and Company
INDUSTRY